Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800968 | 0.89 | CYP3A4 (0.41) | KMT2AMEN1ALDH1A1GAARECQL | |
| SCHEMBL1798595 | 0.87 | LMNA (0.46) | KMT2AMEN1ALDH1A1GAARECQL | |
| SCHEMBL1803451 | 0.85 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL1801173 | 0.85 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3917728 | 0.83 | SMN1; SMN2 (0.39) | KMT2AGAASMN1; SMN2 | |
| SCHEMBL1800500 | 0.83 | MEN1 (0.41) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1803052 | 0.83 | SMN1; SMN2 (0.46) | KMT2AMEN1ALDH1A1GAALMNA | |
| SCHEMBL2934783 | 0.83 | CCR5 (0.40) | KMT2AMEN1ABL1RIN1ALDH1A1 | |
| SCHEMBL1800768 | 0.82 | KMT2A (0.43) | KMT2AMEN1ALDH1A1RECQLLMNA | |
| SCHEMBL1809243 | 0.82 | AVPR1A (0.50) | KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | KMT2A 4267/4885MEN1 1474/4885ABL1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.